%0 Journal Article
%T Intranasal rifampicin for Alzheimer's disease prevention
%A Akiko Tanaka
%A Akira Yamamoto
%A Ayumi Sakai
%A Takami Tomiyama
%A Toshiyasu Sakane
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2018
%R 10.1016/j.trci.2018.06.012
%X Oral rifampicin has been shown to significantly reduce amyloid ¦Â (A¦Â) and tau pathologies in mice. However, it shows occasional adverse effects such as liver injury in humans, making its use difficult for a long period
%K Intranasal
%K Rifampicin
%K A¦Â oligomers
%K Hepatotoxicity
%K Pharmacokinetics
%K Prevention
%K Alzheimer's disease
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076366/